Pfizer scraps daily weight loss pill after liver injury in one patient

Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said in a statement. They added that the patient's liver enzymes "recovered rapidly" after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron. The statement suggests that the patient's liver enzymes were ...